Validate your protocol design before it's locked
Compare your endpoint choice, enrollment assumptions, and indication against thousands of historical Phase 2 oncology trials. See what similar teams encountered and how they responded — sourced to specific trials.
Protocol amendments cost $500K–$1M+ each. Most are avoidable.
Our analysis of 22,704 Phase 2 oncology trials found that 36.1% of documented terminations were caused by slow accrual — not drug failure, not safety signals. Enrollment assumptions that were wrong before the first patient was screened.
Protocol design tools help you write protocols faster. Analytics platforms help you run trials better. But nothing sits in the “before finalization” slot to validate design choices against what actually happened in similar trials.
Protocol Risk Scan fills that gap.
Three steps to a validated protocol
Input your protocol parameters
Indication, phase, proposed primary endpoint, endpoint type, sample size, key eligibility criteria. A guided form — takes 5–10 minutes.
We analyze against historical precedent
Your design parameters are compared against thousands of similar trials from ClinicalTrials.gov. Endpoint precedent, termination patterns, enrollment benchmarks — all sourced to specific NCT IDs.
You receive a decision-validation report
A structured report showing what teams in comparable situations encountered and how they responded. Not predictions — precedent. Framed to strengthen your protocol rationale, not critique it.
What your decision-validation report includes
Every finding cites specific trials. Every pattern is sourced to real NCT IDs. Framed as historical precedent to strengthen your rationale — not critique your choices.
Endpoint precedent analysis
How did similar endpoint choices perform in your indication? What termination and completion rates did comparable trials experience?
Enrollment feasibility benchmark
How do your enrollment assumptions compare to completed trials? What percentage of similar trials terminated due to slow accrual?
Indication-specific patterns
What is the base termination rate for your indication? Which design characteristics correlate with completion in your therapeutic area?
Comparable trial table
5–10 most similar trials with design parameters, outcomes, and NCT IDs. Real precedent you can cite in steering committee discussions.
Medical directors and biostatisticians designing Phase 2 oncology protocols
Protocol Risk Scan is built for teams who want to validate their design choices with evidence before protocol lock — not after the first amendment.
It's not a drafting tool, not an analytics dashboard, and not a prediction model. It's a memory system for the industry — surfacing what similar teams encountered so you can design with precedent, not just intuition.
Run the analysis on your protocol
We'll compare your endpoint choice, enrollment assumptions, and indication against similar historical trials — and show you what those teams encountered.
Request a Protocol Risk Scan